InvestorsHub Logo
Followers 5
Posts 859
Boards Moderated 0
Alias Born 09/28/2012

Re: Fred Kadiddlehopper post# 5445

Wednesday, 01/24/2018 3:12:05 PM

Wednesday, January 24, 2018 3:12:05 PM

Post# of 8521
I agree with your points but Goldman initiated Halo with a Neutral rating this morning, which together with Pfizer's news "Pfizer's biosimilar candidate to Roche's Rituxan/MabThera shows equivalence in comparative lymphoma study" may be one of the reasons for the drop today.

I think we need some more good news to get to $21 and, especially to get to $25. I doubt royalties for Q4 will do it - perhaps a new Enhanze deal, more milestone payments with Perjeta/Herceptin in Phase 3, Roche filing SC Harceptin in US etc.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News